Abstract:e17565 Background: BRCA1 and BRCA2 are tumour suppressor genes, involved in the homologous repair of double-stranded DNA breaks, located at 17q21.31 and 13q13.1, respectively. Germline BRCA1/2 mutations are identified in 13-15% of ovarian cancers (OC), while an additional 5-7% of ovarian cancers harbor somatic BRCA1/2 mutations among foreign populations. To determine the landscape of germline and somatic pathogenic BRCA1 and BRCA2 alterations in Chinese patients with ovarian cancer tested by next‐generation sequencing (NGS), with the aim of defining the best strategy to be implemented in future routine testing. Methods: 472 normal-paired samples from Chinese patients with ovarian cancers were analyzed using hybridization capture-based next generation sequencing. Somatic and germline mutations were identified including 500 genes associated with tumor development. Sequencing data were analyzed to call tumor specific single nucleotide variants (SNV), small insertions and deletions (InDels), copy number alterations (CNA) and gene fusions and rearrangements. Results: Overall, 472 ovarian cancer patients underwent somatic and/or germline NGS analysis, the BRCA1 and BRCA2 genes sequenced in this study covers all targeted coding exons and exon-intron boundaries. Among these patients, 54/472 (11.4%) patients carried BRCA( BRCA1/2) mutations. Inside, there were 43/472 (9.1%) patients occurred somatic BRCA mutations, 62.8% (27/43) of variants were in BRCA1 and 37.2% (16/43) were in BRCA2. Furthermore, 3 cases carried BRCA1 and BRCA2 somatic co-mutation, of which only 1 showed BRCA1/ BRCA2 copy number losses. In 54 OC patients who carried BRCA mutations, 10 patients occured copy number alterations, of which 6 patients showed BRCA1 copy number losses, 4 patients showed BRCA2 copy number losses, and 1 patient showed BRCA2 copy number gains. Germline BRCA variant was detected in 18/472 (3.8%) patients, 66.7% (12/18) of variants were in BRCA1 and 33.3% (6/18) were in BRCA2. Of the 12 BRCA1 germline mutations, 11 were pathogenic heterozygous mutations (c.2679_2682del; c.2101_2102del; c.5085_5086insT; c.1660G > T; c.4810C > T; c.1504_1508del; c.1465G > T; c.1480C > T; c.2110_2111del; c.4185+1G > A; c.81-2A > G), one was likely pathogenic heterozygous mutation (c.5216A > G). Of the 6 BRCA 2 germline mutations, four were pathogenic heterozygous mutations (c.5722_5723del; c.5291C > G; c.5164_5165del; c.3109C > T), one was likely pathogenic heterozygous mutation (c.869_870del), and one was uncertain significance heterozygous mutation (c.7976+3A > G). Conclusions: This study revealed the molecular features of BRCA1 and BRCA2 in Chinese ovarian cancer patients, which could help to identify therapeutic targets and personalize therapy management, leading to improved patient outcomes as predictive biomarkers or platinum-based therapy.

A novel BRCA2 mutation in prostate cancer sensitive to combined radiotherapy and androgen deprivation therapy

A Novel Germline BRCA2 Mutation in a Chinese Patient with Prostate Cancer Sensitive to Platinum Chemotherapy: a Case Report.

Identification of <i>BRCA1</i>:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients

Case Report: Co-Existence of BRCA2 and PALB2 Germline Mutations in Familial Prostate Cancer With Solitary Lung Metastasis

Analysis of BRCA Germline Mutations in Chinese Prostate Cancer Patients

Targeting BRCA‐mutant Biliary Tract Cancer: Current Evidence and Future Perspectives

BRCA1 As a Potential Human Prostate Tumor Suppressor: Modulation of Proliferation, Damage Responses and Expression of Cell Regulatory Proteins

BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer

Prostate Ductal Adenocarcinoma with MLH1 Copy Number Loss, Microsatellite Instability High and BRCA2 Mutation

BRCA2 mutations in familial breast cancer with prostate cancer: a case report and literature review

Multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with BRCA mutations: a case report and literature review

The landscape of BRCA1 and BRCA2 alterations in Chinese ovarian cancer patients.

Genomic Analysis of Castration Sensitive and Resistant Prostate Cancer Patients by Multiple-Gene Targeted Sequencing.

BRCA2 , ATM , and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression

P1.03-27 Somatic Mutations in BRCA2 Genes Are Associated with Prognosis in Chinese Non-Small-Cell Lung Cancer Patients

Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing

A Novel Germline Mutation of BRCA1 and Integrated Analysis with Somatic Mutation in a Chinese Multi-Cancer Family.

Circulating Tumor DNA-targeted Sequencing to Reveal Germline and Somatic Alterations That Can Guide Decision-Making in Metastatic Castration-Resistant Prostate Cancer.

Brca2 Mutation Should Be Screened Routinely And Early As A Poor Prognostic Biomarker In Prostate Cancer Patients With A Family History Of Cancer

Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study

Germline Mutations in DNA Repair Genes in a Large Series of Unselected Chinese Prostate Cancer Patients.